The Negative Impact of Sarcopenia on Hepatocellular Carcinoma Treatment Outcomes

Annalisa Cespiati,Daniel Smith,Rosa Lombardi,Anna Ludovica Fracanzani

DOI: https://doi.org/10.3390/cancers16132315

2024-06-25

Cancers

Abstract:Introduction: Hepatocellular carcinoma (HCC) represents a major global health concern, characterized by evolving etiological patterns and a range of treatment options. Among various prognostic factors, sarcopenia, characterized by loss of skeletal muscle mass, strength, and function, has emerged as a pivotal contributor to HCC outcomes. Focusing on liver transplantation, surgical resection, locoregional treatments, and systemic therapies, this review aims to analyze the impact of sarcopenia on HCC treatment outcomes, shedding light on an underexplored subject in the pursuit of more personalized management. Methods: A comprehensive literature review was conducted by searching peer-reviewed articles on sarcopenia and treatment outcomes in patients with HCC from inception up to October 2023. Results: Sarcopenia was found to be prevalent among HCC patients, exhibiting different occurrence, possibly attributable to diverse diagnostic criteria. Notably, despite variations in studies utilizing skeletal muscle indices, sarcopenia independently correlated with lower overall survival (OS), recurrence-free survival (RFS), and progression-free survival (PFS) across surgical (both transplantation and resection), locoregional, and systemic therapies, including tyrosine-kinase inhibitors (TKIs) and immune-checkpoint inhibitors (ICIs). Moreover, a link between sarcopenia and increased rate and severity of adverse events, particularly in surgery and TKIs recipients, and larger tumor size at diagnosis was observed. While baseline sarcopenia negatively influenced treatment outcomes, alterations in muscle mass post-treatment emerged as primary determinants of reduced OS. Conclusions: Sarcopenia, either present before or after HCC treatment, negatively correlates with response to it, across all etiologies and therapeutic strategies. Although only a few studies have evaluated the impact of supervised physical activity training on muscle mass and OS after HCC treatment, it is crucial to evaluate the presence of sarcopenia before treatment initiation, to better stratify patients' prognosis, thus performing a more tailored approach, and identify therapies able to restore muscle mass in HCC patients. Conversely, the impact of sarcopenia on HCC recurrence and extrahepatic spread remains inadequately explored.

oncology

What problem does this paper attempt to address?

This paper aims to explore the negative impact of sarcopenia on the treatment outcomes of hepatocellular carcinoma (HCC). Specifically, the study analyzes how sarcopenia affects various treatment methods for HCC, including liver transplantation, surgical resection, locoregional therapies (such as transarterial chemoembolization [TACE]), and systemic therapies (such as tyrosine kinase inhibitors [TKI] and immune checkpoint inhibitors [ICI]). The paper points out that sarcopenia is prevalent among HCC patients and is independently associated with lower overall survival, recurrence-free survival, and progression-free survival. Additionally, sarcopenia increases the incidence and severity of adverse events in both surgical and systemic treatments. The study emphasizes the importance of assessing sarcopenia before initiating HCC treatment to better predict patient prognosis and develop personalized treatment plans. However, the impact of sarcopenia on HCC recurrence and extrahepatic spread remains unclear, necessitating further research in this area. Overall, this paper highlights the importance of considering sarcopenia in HCC management and may prompt the search for treatments that address muscle loss in these patients, thereby improving treatment outcomes and patient care.